1. Search Result
Search Result
Results for "

S1P receptor subtypes 5 (S1P5)

" in MedChemExpress (MCE) Product Catalog:

7699

Inhibitors & Agonists

40

Screening Libraries

26

Fluorescent Dye

80

Biochemical Assay Reagents

1014

Peptides

198

Inhibitory Antibodies

504

Natural
Products

1732

Recombinant Proteins

639

Isotope-Labeled Compounds

293

Antibodies

43

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101265

    S1P receptor agonist 1

    LPL Receptor Inflammation/Immunology
    Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
    Icanbelimod
  • HY-12288
    Ozanimod
    2 Publications Verification

    RPC-1063

    LPL Receptor Neurological Disease Inflammation/Immunology
    Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) [1].
    Ozanimod
  • HY-12288A
    Ozanimod hydrochloride
    2 Publications Verification

    RPC-1063 hydrochloride

    LPL Receptor Neurological Disease Inflammation/Immunology
    Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) [1].
    Ozanimod hydrochloride
  • HY-148115

    LPL Receptor Inflammation/Immunology
    S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders [1].
    <em>S1</em>p <em>receptor</em> agonist 2
  • HY-148198

    LPL Receptor Inflammation/Immunology
    S1P5 receptor agonist-1 (example 6) is a potent and selective agonist of S1P5 receptor with an EC50 value of 20 nM [1].
    <em>S1</em>P<em>5</em> <em>receptor</em> agonist-<em>1</em>
  • HY-108496
    Sphingosine-1-phosphate
    5 Publications Verification

    S1P

    Endogenous Metabolite LPL Receptor Endocrinology
    Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors [1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids .
    Sphingosine-<em>1</em>-phosphate
  • HY-P99318

    LT 1009; Anti-Human S1P Recombinant Antibody

    LPL Receptor Cancer
    Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) [1].
    Sonepcizumab
  • HY-12355
    Siponimod
    5+ Cited Publications

    BAF-312

    LPL Receptor Neurological Disease Inflammation/Immunology
    Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research [1] - .
    Siponimod
  • HY-12355A

    BAF-312 hemifumarate

    LPL Receptor Neurological Disease Inflammation/Immunology
    Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research [1] .
    Siponimod hemifumarate
  • HY-12355S

    BAF-312-d11

    LPL Receptor Isotope-Labeled Compounds Neurological Disease Inflammation/Immunology
    Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research [1] .
    Siponimod-d11
  • HY-108490

    LPL Receptor Inflammation/Immunology
    VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the S1P1 and S1P3 receptors (pKi= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC50= 6.58 and 7.07, respectively) [1].
    VPC 23019
  • HY-110291

    Others Neurological Disease
    A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC50s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis [1] .
    A-971432
  • HY-150254

    LPL Receptor Inflammation/Immunology
    SLB1122168 is a potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM [1].
    SLB1122168
  • HY-150254A

    LPL Receptor Inflammation/Immunology
    SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM [1].
    SLB1122168 formic
  • HY-103359

    Ceramidase Cancer
    Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells [1].
    Ceranib<em>1</em>
  • HY-119401
    CAY10444
    1 Publications Verification

    BML-241

    LPL Receptor Cancer
    CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca2+ in HeLa cells expressing S1P3 receptors [1].
    CAY10444
  • HY-16734A

    MT-1303 hydrochloride

    LPL Receptor Cancer
    Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
    Amiselimod hydrochloride
  • HY-108496S

    S1P-d7

    Endogenous Metabolite LPL Receptor Endocrinology
    Sphingosine-1-phosphate-d7 is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].
    Sphingosine-<em>1</em>-phosphate-d7
  • HY-12005
    Fingolimod hydrochloride
    25+ Cited Publications

    FTY720

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator [1] .
    Fingolimod hydrochloride
  • HY-108495

    ML248

    LPL Receptor Cardiovascular Disease
    CYM50308 (ML248) is a potent, selective and high affinity sphingosine-1-phosphate receptor 4 (S1P4-R) agonist with an EC50 of 56 nM. CYM50308 displays 37-fold more selective for S1P4-R than S1P5-R. CYM50308 has no activity at S1P1-R, S1P2-R and S1P3-R subtypes at concentrations up to 25 μM [1].
    CYM50308
  • HY-148801

    LPL Receptor Inflammation/Immunology
    Tamuzimod is a potent immunomodulator. Tamuzimod has S1P Receptor modulatory activity with EC50s <1 μM [1] .
    Tamuzimod
  • HY-15382
    FTY720 (S)-Phosphate
    1 Publications Verification

    (S)-FTY720P; (S)-FTY720 phosphate

    LPL Receptor Inflammation/Immunology
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
    FTY720 (S)-Phosphate
  • HY-15382A

    LPL Receptor Inflammation/Immunology
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
    (S)-FTY720-phosphonate
  • HY-12005R

    FTY720 (Standard)

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator [1] .
    Fingolimod hydrochloride (Standard)
  • HY-12685

    ONO-4641

    LPL Receptor Neurological Disease
    Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.
    Ceralifimod
  • HY-13447A
    PF429242 dihydrochloride
    5+ Cited Publications

    Fatty Acid Synthase (FASN) Virus Protease Infection Metabolic Disease
    PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM [1].
    PF429242 dihydrochloride
  • HY-13447

    Fatty Acid Synthase (FASN) Virus Protease Infection Metabolic Disease
    PF429242 is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM [1].
    PF-429242
  • HY-116147

    LPL Receptor Apoptosis Cancer
    Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity [1] .
    Ceranib-2
  • HY-139094

    LPL Receptor Metabolic Disease
    A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [ 3H]dhS1P increase [1] .
    A6770
  • HY-15381

    FTY720 phosphate

    LPL Receptor Infection Neurological Disease Inflammation/Immunology
    Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases [1].
    Fingolimod phosphate
  • HY-N2553

    LPL Receptor Metabolic Disease
    4-Deoxypyridoxine 5'-phosphate is a Pyridoxal 5'-phosphate analogue and a sphingosine 1-phosphate (S1P) inhibitor. 4-Deoxypyridoxine 5'-phosphate inhibits ornithine decarboxylase activity with a Ki of 60 μM. 4-Deoxypyridoxine 5'-phosphate is a competitive inhibitor of the activation of glutamate apodecarboxylase by Pyridoxal 5'-phosphate (Ki of 0.27 μM) and strongly inhibits glutamate-dependent labeling of glutamate decarboxylase [1] .
    4-Deoxypyridoxine <em>5</em>'-phosphate
  • HY-14113

    Others Inflammation/Immunology
    2-Acetyl-5-tetrahydroxybutyl imidazole is a potent sphingosine-1-phosphate (S1P) lyase inhibitor in vivo.
    2-Acetyl-4-tetrahydroxybutyl imidazole
  • HY-111021
    ASP-4058
    1 Publications Verification

    LPL Receptor Inflammation/Immunology
    ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile [1].
    ASP-4058
  • HY-111021A

    LPL Receptor Inflammation/Immunology
    ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile [1].
    ASP-4058 hydrochloride
  • HY-19511

    GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
    GSK2018682
  • HY-108494

    LPL Receptor Cardiovascular Disease
    CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonist with an EC50 of 45 nM. CYM50260 displays no activity against S1P1-R, S1P2-R, S1P3-R and S1P5-R [1].
    CYM50260
  • HY-149004B

    LPL Receptor Inflammation/Immunology
    SLF1081851 (hydrochloride) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (hydrochloride) plays a key role in the development and immune system [1].
    SLF1081851 hydrochloride
  • HY-11063
    Fingolimod
    25+ Cited Publications

    FTY720 free base

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant [1].
    Fingolimod
  • HY-149004
    SLF1081851
    1 Publications Verification

    LPL Receptor Inflammation/Immunology
    SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system [1] .
    SLF1081851
  • HY-15425
    PF-543
    5+ Cited Publications

    Sphingosine Kinase 1 Inhibitor II

    SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 is >100-fold selectivity for SPHK1 over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy [1] .
    PF-543
  • HY-15425B

    Sphingosine Kinase 1 Inhibitor II hydrochloride

    SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy [1] .
    PF-543 hydrochloride
  • HY-100675
    JTE-013
    4 Publications Verification

    LPL Receptor Apoptosis Cancer
    JTE-013 is a potent and specific S1P2 (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P2 with IC50s of 17 nM and 22 nM, respectively [1].
    JTE-013
  • HY-148292

    LPL Receptor Cardiovascular Disease Inflammation/Immunology
    C16-Sphingosine-1-phosphate is a derivative of Sphingosine-1-phosphate and also an endogenous ligand for the EDG/S1P receptor. C16-Sphingosine-1-phosphate can be used in the research of angiogenesis, inflammation, and cardiovascular diseases [1].
    C16-Sphingosine-<em>1</em>-phosphate
  • HY-120268A

    SphK Inflammation/Immunology Cancer
    SLM6031434 hydrochloride is a highly selective sphingosine kinase 2 (SphK2) inhibitor with Kis of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 hydrochloride decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 hydrochloride has the potential for renal fibrosis research [1] .
    SLM6031434 hydrochloride
  • HY-149004A

    LPL Receptor Inflammation/Immunology
    SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system [1] .
    SLF1081851 TFA
  • HY-15425A
    PF-543 Citrate
    5+ Cited Publications

    Sphingosine Kinase 1 Inhibitor II Citrate

    SphK LPL Receptor Apoptosis Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy [1] .
    PF-543 Citrate
  • HY-156408

    LPL Receptor Inflammation/Immunology
    Spns2-IN-1 is a potent inhibitor of Spns2-dependent S1P transport (Spns2), with IC50 of 1.4±0.3 μM that plays an important role in immune response [1].
    Spns2-IN-<em>1</em>
  • HY-11063S1

    FTY720-d4

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant[1].
    Fingolimod-d4 hydrochloride
  • HY-11063S

    FTY720 free based-d4

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].
    Fingolimod-d4
  • HY-113934

    L-threo-Sphingosylphosphorylcholine

    LPL Receptor Cancer
    L-threo Lysosphingomyelin (d18:1) (L-threo-Sphingosylphosphorylcholine) is an endogenous bioactive sphingolipid. L-threo Lysosphingomyelin (d18:1) is a potent S1P receptor agonist with EC50s of 19.3, 131.8, and 313.3 nM for hS1P1, hS1P3, and hS1P2, respectively [1].
    L-threo Lysosphingomyelin (d18:<em>1</em>)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: